SCOTTSDALE, Ariz. and MEDFORD, Mass., March 16, 2016 /PRNewswire/ -- IVF PHOENIX and INVO Bioscience (OTC: IVOB) are pleased to announce that IVF PHOENIX will be the first fertility treatment center on the west coast to offer the FDA cleared INVOcell™ Intravaginal Culture System and patented INVO procedure as a treatment option for patients diagnosed with infertility.
The patented INVOcell is used for the incubation of eggs and sperm during fertilization of early embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, the INVOcell utilizes the women's vagina as a natural incubator to support fertilization and embryo development. During an INVO procedure, the patient undergoes a natural or low stimulation cycle. Once the eggs are retrieved and sperm is collected, they are placed into the INVOcell device. The INVOcell device is immediately placed in the vaginal cavity to incubate the eggs and sperm, allowing a more natural fertilization and development of the embryo to take place in its earliest stage. Following vaginal incubation, the device is removed allowing for the transfer of embryos. This revolutionary in vivo method of vaginal incubation offers patients a more natural and intimate experience.
Dr. John Couvaras, IVF PHOENIX's Medical Director, commented, "We are very excited to be offering the INVO treatment to our patients and are encouraged about INVO's success rates while also offering a treatment option that can limit the number of failed fertility cycles, including IUI cycles."
For many patients undergoing Intrauterine Insemination (IUI), increasing the frequency of insemination does not provide a significant increase in cycle pregnancy rate.1 Intrauterine insemination (IUI) is a procedure that bypasses the cervix and places sperm into a woman's uterus around the time of ovulation. This procedure is performed to improve a woman's chance of getting pregnant. Overall, if inseminations are performed monthly with fresh or frozen sperm, success rates can be as high as 10-20% per cycle depending on whether fertility medications are used, age of the female partner, and infertility diagnosis, as well as other facts that could impact the success of the cycle. However, the reality is that many will seek to do this treatment multiple times before getting pregnant.
Dr. Couvaras added, "Our patients ride the rollercoaster of hope after numerous attempts of IUI and now have a new fertility treatment option not previously available. This treatment not only increases the patient's chances of conceiving but is also earmarked as a lower cost option for widespread adoption compared to the current aggregated 3-4 attempts at IUI."
INVOcell has gained national attention over the last year from the infertility community as a safe, effective, and low cost fertility treatment option. In clinical studies, the INVOcell procedure produced pregnancy rates equivalent to traditional IVF treatments. In 2014, the American Society of Reproductive Medicine (ASRM) endorsed INVOcell as safe, effective, and lower cost option for treating infertile patients.2
"We are optimistic and very excited about our partnership with IVF PHOENIX and the launch of the INVOcell System and INVO procedure in the U.S.," stated Kathleen Karloff, Chief Executive Officer for INVO Bioscience. "This represents an important first step, with more to follow in the coming months, as we move forward in opening the doors to the enormous U.S. marketplace and the introduction of the INVOcell throughout the country."
About IVF PHOENIX
IVF PHOENIX has been helping make dreams of a family come true for more than 25 years under the direction of board certified Reproductive Endocrinologist, John L Couvaras MD. With offices in Scottsdale and Mesa, the centers offer state-of-the-art fertility treatments to residents throughout the state of Arizona. IVF PHOENIX offers the comprehensive suite of services including IVF, Immunological protocols as well as reproductive surgery. The expertise offers a customized, integrative approach to treat the whole patient on the best path to parenthood. Visit ivfphoenix.com to learn more.
About INVOcell
The INVOcell is used for the incubation of eggs and sperm during fertilization of early embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, the INVOcell device and procedure is an in vivo method that utilizes the women's vagina as a natural incubator to support embryo development. The key features and benefits of the INVOcell device and procedure include: providing a more natural and stable vaginal incubation than in a conventional IVF incubator; providing psychological benefits to patients/couples and promoting greater involvement by couples; reducing the risk of incorrect embryo transfers; and reducing the cost of infertility treatments and increasing geographic accessibility.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology.
For more information, visit INVO Bioscience's website at www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
| CONTACTS: |
IVF PHOENIX |
| Rhoda Rizkalla |
|
| 602-418-2006 |
|
| INVO Bioscience Inc. |
|
| Investors: |
|
| Katie Karloff |
|
| 978-878-9505 ext. 504 |
RELATED LINKS
Photo - http://photos.prnewswire.com/prnh/20160315/344706
Logo - http://photos.prnewswire.com/prnh/20160315/344704LOGO
Logo - http://photos.prnewswire.com/prnh/20160315/344705LOGO
SOURCE INVO Bioscience
Share this article